



### Primary Aldosteronism

Marina Nodelman, MD

The Diabetes, Endocrinology and Metabolism Department


#### **Adrenal Steroids**





#### Renin-Angiotensin-Aldosterone System Angiotensin I Angiotensinogen Renin from JGA Converting **α**<sub>2</sub>-globulin from liver enzyme inlung Angiotensin II Lung Aldosterone Na\* and H<sub>2</sub>O retention Adrenal Increased blood volume Increased blood pressure Copyright ⊚ motifolio.com 9111182

## Ion Transport in Collecting Tubule Principal Cells





- Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension.
- 1-2% in unselected patients with hypertension.
- 10-20% in patients with resistant hypertension.
- 1% of adrenal incidentaloma = aldosteronoma.



 Resistant hypertension - failure to achieve goal blood pressure (BP) despite adherence to an appropriate three-drug regimen including a diuretic.

Refractory hypertension – failure to control the BP even with maximal medical therapy (four or more drugs with complementary mechanisms given at maximal tolerated doses) under the care of a hypertension specialist.



Secondary aldosteronism	Primary aldosteonism	
Renin dependent	Generally autonomous (ACTH dependent?)	Aldo secretion
or N ↑	$\downarrow\downarrow\downarrow$	Renin level
<ul> <li>HTN (renovascular, malignant, renal disease)</li> <li>CHF</li> <li>Cirrhosis</li> <li>Nephrotic syndrome</li> <li>Bartter's syndrome</li> </ul>		

#### м

#### Clinical Features of Primary Aldosteronism

- Hypertension
- Hypokalemia only 40-50%
- Lack of edema
- Metabolic alkalosis
- Mild hypernatremia, hypomagnesemia
- ↑ GFR, polyuria, proteinuria, CRF
- Muscle weakness&cramps (hypokalemia less than 2.5 meq/L)
- LVH, MI, CVA, AF

# Subtypes of Primary Aldosteronism

Subtype		Relative frequency (%)	
Idiopathic hyperaldosteronism	65	Hyperplasia	
Aldosterone-producing adenoma	30	Adenoma	
Primary unilateral adrenal hyperplasia	3		
Aldosterone-producing adrenocortical carcinoma	1		
Aldosterone-producing ovarian tumor	<1		
Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism)	<1		
Familial hyperaldosteronism type II (familial occurrence of aldosterone-producing adenoma and/or idiopathic hyperaldosteronism)			



Idiopatic Aldosteronism	Aldosteronoma (Conn's)	
older	younger	age
male	female	sex
↓↓ or ↓	$\downarrow\downarrow\downarrow$	K
↓↓ or ↓	$\downarrow\downarrow\downarrow$	PRA
bilateral enlargement or normal	unilateral adenoma	CT findings
resistant HTN	↓ BP <b>N</b> or	Response to surgery

#### Screening for Primary Aldosteronism

- severe hypertension (>160/100 mmHg) or drug-resistant hypertension
- HTN and spontaneous or diuretic-induced hypokalemia
- hypertension with adrenal incidentaloma
- hypertension and a family history of early onset hypertension or CVA at a young age (<40 years)</li>
- case detection for all hypertensive first-degree relatives of patients with PA is recommend

#### Screening (cont.)

- Plasma Aldosterone-to-Renin ratio
- mid-morning, after the patient has been up for at least 2 hours and seated for 5-15 minutes
- have to be withdrawn for at least 4 weeks:
- Spironolactone, eplerenone, amiloride, and triamterene
- Potassium-wasting diuretics
- Confectionary licorice, chewing tobacco
- Results:
- ✓ PRA↓
- PAC ≥15 ng/dL (416 pmol/L)
- ✓ PAC/PRA ≥20

#### 10

#### Confirmation of the Diagnosis

Oral sodium loading
 24-h urine Na excretion >200 meq
 Urine Aldo excretion>12 mkg/24h

Saline infusion test
 PAC>10 ng/dL (>277 pmol/L)
 normal <5 ng/dL</li>


TABLE 2. Medications that have minimal effects on plasma aldosterone levels and can be used to control hypertension during case finding and confirmatory testing for primary aldosteronism

Drug	Class	Usual dose	Comments
Verapamil slow-release	Non-dihydropyridine antagonist calcium channel	90–120 mg twice daily	Use singly or in combination with the other agents listed in this Table.
Hydralazine	Vasodilator	10–12.5 mg twice daily, increasing as required	Commence verapamil slow-release first to prevent reflex tachycardia. Commencement at low doses reduces risk of side effects (including headaches, flushing, and palpitations).
Prazosin hydrochloride	Alpha-adrenergic blocker	0.5-1 mg two to three times daily, increasing required	Monitor for postural hypotension.
Doxazosin mesylate	Alpha-adrenergic blocker	1–2 mg once daily, increasing as required	Monitor for postural hypotension.
Terazosin hydrochloride	Alpha-adrenergic blocker	1–2 mg once daily, increasing as required	Monitor for postural hypotension.

#### **Imaging**

- CT scan
- MRI
- Adrenal venous sampling
- lodocholesterol scintigraphy


#### Adenoma vs. Bilateral Hyperplasia









#### Diagnosis of Primary Aldosteronism



#### Adrenal Venous Sampling







#### **Treatment**

HTN is improved in all and is cured in .35-60% of pt

Laparoscopic adrenalectomy	APA
	PAH
Medical treatment Aldactone, eplerenone, amiloride, triamterene	IAH
GK treatment	GRA
+Open adrenalectomy chemotherapy	Adrenal carcinoma

